文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

在HIV诊疗中整合兴奋剂使用障碍治疗:列联管理试点实施效果研究

Integrating HIV and Stimulant-Use Disorder Treatment: A Pilot Implementation Effectiveness Trial of Contingency Management in HIV Care.
PubMed 文献 · Clin Infect Dis · 2026-01-01

本研究在安全网HIV诊所开展12周单臂试点,对31名合并兴奋剂使用障碍的HIV感染者实施每周列联管理(CM)。定性访谈提示将CM嵌入HIV诊疗可提升可及性、有效性与实施可行性。

要点

  • 将CM嵌入HIV诊疗可行,参与者认为激励支持服药自我效能。
  • 出席率仅42%,需进一步评估可扩展性与保留策略。

核心结论

  • 将针对兴奋剂使用和/或抗逆转录病毒治疗依从性的列联管理嵌入HIV诊疗,与兴奋剂使用减少和病毒抑制改善相关。
  • 整合HIV与兴奋剂使用障碍管理的可扩展性值得进一步评估。

研究设计与样本

  • 12周、单臂、实施-效果试点研究,在安全网HIV诊所每周开展列联管理。
  • 纳入31名合并兴奋剂使用障碍的HIV感染者。

主要发现

  • 77%使用甲基苯丙胺,35%可卡因,19%芬太尼;基线仅17/31(55%)病毒抑制。
  • 参与者平均出席5/12次访视(42%)。
  • 在26名有入组后访视者中,110次兴奋剂检测中61次(56%)阴性,91次替诺福韦检测中89次(98%)阳性。

临床怎么用

  • 在HIV诊疗中嵌入CM,使用床旁替诺福韦检测和兴奋剂检测提供递增激励。
  • 采用支持性、非评判性员工关系可促进实施。

局限性

  • 单臂试点设计,样本量小(31人),出席率低(42%),结果需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Stimulants, including cocaine and methamphetamine, are associated with HIV transmission and viremia. Contingency management (CM), which provides financial incentives for nonreactive urine testing, is first-line treatment for stimulant-use disorder (StUD), yet has been minimally studied or integrated into HIV care. METHODS: We conducted a 12-week, single-arm, implementation-effectiveness pilot of weekly CM in a safety-net HIV clinic for persons with HIV (PWH) who have StUD. Participants received escalating incentives for stimulant-negative and/or tenofovir-reactive point-of-care urine assays. Using the RE-AIM framework, we evaluated Reach (demographics, attendance), Effectiveness (stimulant-negative/tenofovir-positive tests, HIV virologic suppression [VS]), and Implementation. We conducted semi-structured, in-depth participant interviews following intervention completion to explore perceived impact and implementation. RESULTS: From September 2023 to February 2024, we enrolled 31 PWH with StUD: 77% used methamphetamine, 35% cocaine, and 19% fentanyl. Only 17 of 31 (55%) had VS at baseline. Participants attended a mean of 5 of 12 visits (42%). Among PWH who attended postenrollment visits (26/31), 61 of 110 (56%) stimulant tests were negative and 98% (89/91) of tenofovir tests were positive. Postintervention, 88% (23/26) of retained participants achieved VS (P < .01). Qualitative interviews revealed factors enhancing Reach (embedding CM within HIV care), Effectiveness (incentives supporting adherence self-efficacy; program providing structure and motivation), and Implementation (supportive staff relationships, nonjudgmental approach). CONCLUSIONS: Contingency management for stimulant use and/or antiretroviral therapy adherence (using point-of-care tenofovir assays) embedded into HIV care was associated with reduced stimulant use and gains in viral suppression. Scalability of integrating HIV and StUD management using CM merits further evaluation. Clinical Trials Registration. clinicaltrials.gov (NCT06564792).

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Appa A, Steiner G, Baral S, et al. Integrating HIV and Stimulant-Use Disorder Treatment: A Pilot Implementation Effectiveness Trial of Contingency Management in HIV Care. Clin Infect Dis. 2026. PMID: 41505433. doi:10.1093/cid/ciag006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。